Atrium Therapeutics (RNA) vs Spruce Biosciences (SPRB)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Atrium Therapeutics is the larger company by market cap ($141.3 million vs $130.9 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | RNA | SPRB |
|---|---|---|
| Share price | $8.26 | $45.54 |
| Market cap | $141.29M | $130.88M |
| 1-day change | +4.16% | +2.57% |
| YTD return | — | -47.72% |
| 1-year return | — | -71.55% |
| 5-year return | — | -99.82% |
| Forward P/E | — | 9.15 |
| EPS (TTM) | $-5.44 | $-39.12 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $16.77 | $199.20 |
| 52-week low | $7.63 | $40.33 |
| Distance from 52-week high | -50.75% | -77.14% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +202.66% | +224.99% |
| Average volume | 259.35K | 77.75K |
| Shares outstanding | 17.11M | 2.87M |
| Employees | — | 22 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Atrium Therapeutics
RNA stock →Atrium Therapeutics, Inc., a biopharmaceutical company, focuses on delivering ribonucleic acid (RNA) therapeutics to the heart to transform the care for people living with cardiomyopathies. The company's development stage product candidates include ATR 1072, a siRNA-based therapy targeting PRKAG2 for the treatment of PRKAG2 syndrome; and ATR 1086, a siRNA-based therapy targeting PLN for the treatment of PLN cardiomyopathy.
Health Care · Biotechnology: Pharmaceutical Preparations
About Spruce Biosciences
SPRB stock →Spruce Biosciences, Inc. is a biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders.
Health Care · Biotechnology: Pharmaceutical Preparations · 22 employees
RNA vs SPRB FAQ
Which is bigger, Atrium Therapeutics or Spruce Biosciences?
Atrium Therapeutics (RNA) is larger, with a market capitalization of $141.29M compared with $130.88M for Spruce Biosciences (SPRB).
Are Atrium Therapeutics and Spruce Biosciences in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.